Conditions: Dementia With Lewy Bodies (DLB)
Keywords: Lewy Body Disease Dementia Clinical Trial Phase II E2020 donepezil hydrochloride
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 160
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: E2020
Intervention descriptions: intervention 1: Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.

Protocol document: